GOSSAMER BIO INC (GOSS)
US38341P1021 - Common Stock
We assign a fundamental rating of 1 out of 10 to GOSS. GOSS was compared to 568 industry peers in the Biotechnology industry. GOSS may be in some trouble as it scores bad on both profitability and health. GOSS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year GOSS has reported negative net income.
In the past year GOSS has reported a negative cash flow from operations.
GOSS had negative earnings in each of the past 5 years.
GOSS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
GOSS has a better Return On Assets (-20.42%) than 77.17% of its industry peers.
GOSS's Return On Equity of -132.35% is on the low side compared to the rest of the industry. GOSS is outperformed by 61.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.42% | ||
| ROE | -132.35% | ||
| ROIC | N/A |
ROA(3y)-69.97%
ROA(5y)-59.46%
ROE(3y)-791.59%
ROE(5y)-500.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GOSS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for GOSS has been increased compared to 1 year ago.
GOSS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GOSS has an improved debt to assets ratio.
2.2 Solvency
GOSS has an Altman-Z score of -3.82. This is a bad value and indicates that GOSS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.82, GOSS perfoms like the industry average, outperforming 43.19% of the companies in the same industry.
GOSS has a Debt/Equity ratio of 3.64. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of GOSS (3.64) is worse than 83.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.64 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.82 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
GOSS has a Current Ratio of 6.74. This indicates that GOSS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.74, GOSS is doing good in the industry, outperforming 66.37% of the companies in the same industry.
GOSS has a Quick Ratio of 6.74. This indicates that GOSS is financially healthy and has no problem in meeting its short term obligations.
GOSS's Quick ratio of 6.74 is fine compared to the rest of the industry. GOSS outperforms 66.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.74 | ||
| Quick Ratio | 6.74 |
3. Growth
3.1 Past
GOSS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.92%, which is quite impressive.
EPS 1Y (TTM)81.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
GOSS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.44% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y79.49%
EPS Next 2Y21.99%
EPS Next 3Y17.9%
EPS Next 5Y15.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GOSS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GOSS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GOSS's earnings are expected to grow with 17.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.99%
EPS Next 3Y17.9%
5. Dividend
5.1 Amount
GOSS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GOSSAMER BIO INC
NASDAQ:GOSS (12/18/2024, 2:40:58 PM)
0.8118
-0.06 (-6.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap183.95M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.42% | ||
| ROE | -132.35% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.64 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.74 | ||
| Quick Ratio | 6.74 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)81.92%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y79.49%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y